FibromyalgiaPhase 3RESILIENTNCT05273749

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia

A Phase 3 study testing TNX-102 SL Tablet, 5.6 mg in people with Fibromyalgia, run by Tonix Pharmaceuticals, Inc. at 33 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia. Read more about this study

Who is it for?: Ages 18 to 65 years
Conditions the study is for: Fibromyalgia
What is being tested?: TNX-102 SL Tablet, 5.6 mg
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 457 participants
Where: 33 sitesUnited States
Study dates: 6 Apr 2022to 14 Nov 2023
Phase: Phase 3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

The patient is male or female 18 to 65 years of age, inclusive.
The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria)

Who cannot join

The patient has been diagnosed with infectious or inflammatory arthritis (e.g., rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), systemic lupus erythematosus, untreated or active gout (ie, any acute attacks within past 2 years is exclusionary), or meets criteria for other type of systemic autoimmune disease.

Trial locations and contacts

33 sites in 1 country.

City, postcode or hospital

33 sites in 1 country

United States33 sites

Tonix Clinical Site
Albuquerque, New Mexico, 87109
Tonix Clinical Site
Alpharetta, Georgia, 30022
Tonix Clinical Site
Atlanta, Georgia, 30329
Tonix Clinical Site
Austin, Texas, 78737
Tonix Clinical Site
Boston, Massachusetts, 02131
Tonix Clinical Site
Charleston, South Carolina, 29407
Tonix Clinical Site
Charlottesville, Virginia, 22911
Tonix Clinical Site
Cincinnati, Ohio, 45219
Tonix Clinical Site
Covington, Louisiana, 70433
Tonix Clinical Site
Cromwell, Connecticut, 06416
Tonix Clinical Site
Dallas, Texas, 75231
Tonix Clinical Site
Danville, Virginia, 24541
Tonix Clinical Site
Evansville, Indiana, 47714
Tonix Clinical Site
Fort Myers, Florida, 33912
Tonix Clinical Site
Gulfport, Mississippi, 39501
Tonix Clinical Site
Jacksonville, Florida, 32256
Tonix Clinical Site
Kenosha, Wisconsin, 53144
Tonix Clinical Site
McKinney, Texas, 75070
Tonix Clinical Site
Miami Lakes, Florida, 33016
Tonix Clinical Site
New Orleans, Louisiana, 70115
Tonix Clinical Site
Ocala, Florida, 34470
Tonix Clinical Site
Oceanside, California, 92056
Tonix Clinical Site
Oldsmar, Florida, 34677
Tonix Clinical Site
Orlando, Florida, 32801
Tonix Clinical Site
Phoenix, Arizona, 85012
Tonix Clinical Site
Portland, Oregon, 97210
Tonix Clinical Site
Prairie Village, Kansas, 66208
Tonix Clinical Site
Prairieville, Louisiana, 70769
Tonix Clinical Site
Santa Ana, California, 92705
Tonix Clinical Site
Temecula, California, 92591
Tonix Clinical Site
Tulsa, Oklahoma, 74133
Tonix Clinical Site
West Des Moines, Iowa, 50265
Tonix Clinical Site
Williamsville, New York, 14221

Other trials in United States

About this study

Official title: A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia

Conditions: Fibromyalgia
Being tested: TNX-102 SL Tablet, 5.6 mg, Placebo SL Tablet
Keywords: Pain, Sleep, Fibromyalgia, FM
Medical subject headings: Fibromyalgia, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

TNX-102 SL Tablet, 5.6 mgDrug
Also called Low dose cyclobenzaprine sublingual tablets
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Placebo SL TabletDrug
Also called Placebo sublingual tablets
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.

Study groups in NCT05273749
Study group	Role	What they receive
TNX-102 SL Tablet, 5.6 mg	Experimental	1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks. Receives: Drug: TNX-102 SL Tablet, 5.6 mg
Placebo SL Tablet	Placebo comparator	1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks. Receives: Drug: Placebo SL Tablet

What is being measured

The primary outcome is the main question the study is designed to answer.

Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores.
Change from Baseline to the Week 14 endpoint in the diary Numerical Rating Scale (NRS) weekly average of daily self-reported average pain severity scores. Scores range from 0 to 10 where a higher score means worse outcome.
Measured: Baseline (Day -7 to Day -1), Week 14

Secondary outcomes (6)

Proportion of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved" at the Week 14 Endpoint
The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.
Measured: Week 14
Change From Baseline in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score at the Week 14 Endpoint
Change from Baseline in the FIQ-R Symptoms domain score at the Week 14 endpoint. Scores on the symptoms domain range from 0 to 90 where a higher score means worse outcome.
Measured: Day 1, Week 14
Change From Baseline in the FIQ-R Function Domain Score at the Week 14 Endpoint
The FIQ-R is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.
Measured: Day 1, Week 14
Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance at the Week 14 Endpoint
The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.
Measured: Day 1, Week 14
Change From Baseline in the PROMIS Score for Fatigue at the Week 14 Endpoint
The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.
Measured: Day 1, Week 14
Change From Baseline in the Weekly Average of the Daily Diary Assessment of Sleep Quality at the Week 14 Endpoint
Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).
Measured: Baseline (Day -7 to Day -1), Week 14

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

6 Apr 202214 Nov 2023

First posted10 Mar 2022
Study start6 Apr 2022
Primary completion14 Nov 2023
Study completion14 Nov 2023

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for FibromyalgiaStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 457 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05273749
Sponsor's protocol ID: TNX-CY-F307
Acronym: RESILIENT
Status last verified: Jan 2025
First submitted: 1 Mar 2022
Last updated: 22 Jan 2025
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: No

Publications

Lederman S, Arnold LM, Vaughn B, Engels JM, Kelley M, Sullivan GM. Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine. Pain Med. 2026 Jan 1;27(1):86-94. doi: 10.1093/pm/pnaf089.
PubMed 40627411

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingObservational study
Daily Cognitive Failures and Medication Adherence in Fibromyalgia
Fibromyalgia
Not yet recruitingObservational study
Agreement Between CSI and IASP Pain Classification in Chronic Cervical Myofascial Pain
Myofascial Pain Syndrome - Neck
Not yet recruiting
Toward Biomarker-Guided Fibromyalgia Treatment With Non-Invasive Vagus Nerve Stimulation
Fibromyalgia
Active, not recruiting
Comparing Instrument-Assisted Soft Tissue Mobilization and Muscle Energy Technique for Myofascial Pain Syndrome in Women
Myofascial Pain Syndrome
Active, not recruiting
PEACE: Comparing Chronic Pain Treatment Options
Chronic Pain, Musculoskeletal Pain

All Fibromyalgia trials

Study at a glance

From the registry record, last updated by the sponsor on 22 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia
ClinicalTrials.gov ID: NCT05273749
Acronym / sponsor ID: RESILIENT / TNX-CY-F307
Conditions: Fibromyalgia
Keywords: Pain, Sleep, Fibromyalgia, FM
Phase: Phase 3
Study type: Interventional
Recruitment status: Completed
Enrolment: 457 participants (actual)
Lead sponsor: Tonix Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
Study start: 6 Apr 2022 (actual)
Primary completion: 14 Nov 2023 (actual)
Study completion: 14 Nov 2023 (actual)
First posted: 10 Mar 2022 (actual)
Results: Posted 20 Dec 2024

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2

Arm	Type	Receives
TNX-102 SL Tablet, 5.6 mg	Experimental	Drug: TNX-102 SL Tablet, 5.6 mg1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
Placebo SL Tablet	Placebo comparator	Drug: Placebo SL Tablet1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.

Who may qualify

Ages: 18 to 65 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (2 listed)

The patient is male or female 18 to 65 years of age, inclusive.
The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria)

Key exclusion criteria (1 listed)

The patient has been diagnosed with infectious or inflammatory arthritis (e.g., rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), systemic lupus erythematosus, untreated or active gout (ie, any acute attacks within past 2 years is exclusionary), or meets criteria for other type of systemic autoimmune disease.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
TNX-102 SL Tablet, 5.6 mgAlso: Low dose cyclobenzaprine sublingual tabletsPatients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.	Drug	TNX-102 SL Tablet, 5.6 mg
Placebo SL TabletAlso: Placebo sublingual tabletsPatients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.	Drug	Placebo SL Tablet

Primary outcome

Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores.
Time frame: Baseline (Day -7 to Day -1), Week 14
Change from Baseline to the Week 14 endpoint in the diary Numerical Rating Scale (NRS) weekly average of daily self-reported average pain severity scores. Scores range from 0 to 10 where a higher score means worse outcome.

6 secondary outcomes

Proportion of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved" at the Week 14 Endpoint
Time frame: Week 14
Change From Baseline in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score at the Week 14 Endpoint
Time frame: Day 1, Week 14
Change From Baseline in the FIQ-R Function Domain Score at the Week 14 Endpoint
Time frame: Day 1, Week 14
Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance at the Week 14 Endpoint
Time frame: Day 1, Week 14
Change From Baseline in the PROMIS Score for Fatigue at the Week 14 Endpoint
Time frame: Day 1, Week 14
Change From Baseline in the Weekly Average of the Daily Diary Assessment of Sleep Quality at the Week 14 Endpoint
Time frame: Baseline (Day -7 to Day -1), Week 14

Results and safety

Results posted to the registry on 20 Dec 2024, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
TNX-102 SL Tablet, 5.6 mg	231	187
Placebo SL Tablet	226	179

Primary outcome: Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores.

Time frame: Baseline (Day -7 to Day -1), Week 14. Least squares mean (95% Confidence Interval). Unit: score on a scale

Measure	TNX-102 SL Tablet, 5.6 mg n = 231	Placebo SL Tablet n = 225
Value	-1.8 (-2.0 to -1.6)	-1.2 (-1.4 to -0.9)

Population analysed: Intention-To-Treat (ITT) population: all patients who were randomized. This is the primary population for efficacy analyses, and patients will be analyzed based on their randomized treatment.

6 secondary outcomes are reported in the full results.

Adverse events

Time frame: 14 Weeks. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
TNX-102 SL Tablet, 5.6 mg	2 of 231 (0.9%)	78 of 231 (33.8%)	0 of 231
Placebo SL Tablet	3 of 226 (1.3%)	4 of 226 (1.8%)	0 of 226

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2025.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 40627411Lederman S, Arnold LM, Vaughn B, Engels JM, Kelley M, Sullivan GM. Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine. Pain Med. 2026 Jan 1;27(1):86-94. doi: 10.1093/pm/pnaf089.
Individual participant dataSharing planned: No

Related trials for Fibromyalgia

Not yet recruitingObservational study
Daily Cognitive Failures and Medication Adherence in Fibromyalgia
Fibromyalgia
Not yet recruitingObservational study
Agreement Between CSI and IASP Pain Classification in Chronic Cervical Myofascial Pain
Myofascial Pain Syndrome - Neck
Not yet recruiting
Toward Biomarker-Guided Fibromyalgia Treatment With Non-Invasive Vagus Nerve Stimulation
Fibromyalgia
Active, not recruiting
Comparing Instrument-Assisted Soft Tissue Mobilization and Muscle Energy Technique for Myofascial Pain Syndrome in Women
Myofascial Pain Syndrome
Active, not recruiting
PEACE: Comparing Chronic Pain Treatment Options
Chronic Pain, Musculoskeletal Pain

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Gregory Sullivan, MD study director

Tonix Pharmaceuticals, Inc.

33 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing TNX-102 SL Tablet, 5.6 mg in people with Fibromyalgia, run by Tonix Pharmaceuticals, Inc. at 33 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 33 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 20 Dec 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores. (time frame: Baseline (Day -7 to Day -1), Week 14). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05273749, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2025.